Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sanofi Opens Company’s First Digital Manufacturing Facility in Massachusetts

Paris-based Sanofi announced the inaugural opening of the company’s first new digital manufacturing facility for biologics production in Framingham, Massachusetts.

Read More »

Favorable court ruling for Vectura and Sandoz vs. GSK

A British court ruled in favor of Vectura Group and the company’s partner Sandoz over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

Read More »

FDA green lights AstraZeneca’s asthma drug Fasenra for self-administration

The U.S. Food and Drug Administration approved self-administration of AstraZeneca’s asthma treatment Fasenra which uses a pre-filled, single-use auto-injector pen.

Read More »

FDA Approves GSK’s Nucala for Children with Severe Eosinophilic Asthma

The FDA greenlit GlaxoSmithKline’s Nucala (mepolizumab) for treating severe eosinophilic asthma in children as young as 6 years.

Read More »

AstraZeneca respiratory business gets boost from three-drug inhaler results

Prospects for AstraZeneca’s respiratory treatments business improved as a three-drug inhaler was shown to ease smoker’s lung and U.S. regulators granted the company’s injectable asthma drug Fasenra special status for a rare lung condition.

Read More »

Sanofi Reports Strong Second-Quarter 2019

Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.

Read More »

FDA approves expanded label for Regeneron/Sanofi’s Dupixent

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc. and Sanofi SA’s drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine.

Read More »

Novartis’ Double-Combo Therapy for Asthma Successful in Phase III Trial

Novartis’ QMF149 met primary and key secondary endpoints in the Phase III QUARTZ clinical trial for asthma.

Read More »

Alphabet’s Verily Inks Collaboration Deal with Big Pharma Companies and Health Systems

Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi, and six major health systems.

Read More »

Sanofi’s Dupixent Approved for Severe Asthma by European Commission

The European Commission approved Dupixent (dupilumab) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide, who are inadequately controlled with high dose inhaled corticosteroid plus another medicinal product for maintenance treatment.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom